SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934
Filed by the registrant [x]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[ ] Preliminary proxy statement
[ ] Confidential, for use of the commission only (as permitted
by Rule 14a-6(e)(2))
[ ] Definitive proxy statement
[ ] Definitive additional materials
[X] Soliciting material pursuant to Section 240.14a-11(c) or
Section 240.14a-12
DRAGON PHARMACEUTICAL, INC.
(Name of Registrant as Specified in Its Charter)
------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required
[ ] Fee computed on table below per Exchange Act Rules 14a-6(I)
and 0-11.
1) Title of each class of securities to which transaction
applies:
-------------------------------------------------
2) Aggregate number of securities to which transactions
applies:
--------------------------------------------------
3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11. (Set forth the
amount on which the filing fee is calculated and state how
it was determined):
----------------------------------
4) Proposed maximum aggregate value of transaction:
-----------------------------------------
5) Total fee paid:
------------------------------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by
Exchange Act Rule 0-11(a)(2) and identify the filing for which
the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the form or schedule
and the date of its filing.
(1) Amount Previously Paid:
-----------------------------------
(2) Form, Schedule or Registration Statement No.:
--------------
(3) Filing Party:
---------------------------------------------
(4) Date Filed:
-----------------------------------------------
Dragon Commences Shipment of Erythropoietin (EPO)
to Three New International Markets :
Dominican Republic, Trinidad-Tobago and Kosovo
Vancouver, BC- November 15, 2004. - Dragon Pharmaceutical Inc. (OTC BB: DRUG;
TSX: DDD; BBSE:DRP) is pleased to announce that Dragon's recombinant
Erythropoietin (EPO) products have been granted market approvals in the
Dominican Republic and Trinidad-Tobago as advised by Dragon's licensees. In
addition, the health authority of Kosovo has accepted our licensee's application
for the market approval and under such a circumstance, Dragon's licensee is
allowed to bid for government tender and has since won such a tender. Initial
shipment of our EPO products to all three new international markets has started
during the fourth quarter of 2004. Together with the already approved markets in
China, Brazil, India, Egypt, Peru and Ecuador, Dragon's EPO products are being
marketed in a total of 9 countries across Asia, Central and South America, the
Middle East and Eastern Europe.
"Even though these three new markets do not represent a large market size, it is
important and encouraging to Dragon that our EPO is being approved and becomes
available in ever more countries around the globe. This represents a most
valuable confirmation of the quality and the acceptability of our EPO. It
further validates our international strategy and rewards the efforts made by
Dragon and our licensees. We consider this especially important since we plan to
leverage our combined international regulatory and marketing expertise to
commercialize other pharmaceutical products coming from the proposed and
actively pursued acquisition of Oriental Wave", said Dr. Alexander Wick,
President and CEO of Dragon.
About Dragon Pharmaceutical Inc.
-------------------------------
Dragon Pharmaceutical Inc. is an international bio-pharmaceutical company
headquartered in Vancouver, Canada, with a GMP production facility in Nanjing,
China. Dragon's EPO products are being marketed in 9 countries: China, India,
Egypt, Brazil, Peru, Ecuador, Trinidad-Tobago, Dominican Republic and Kosovo.
Additional regulatory submissions are in progress throughout Central and Eastern
Europe, Asia, Latin America, the Middle East and Africa, and the Company is
preparing to enter the European Union market.
Dragon Pharmaceutical Inc. announced entering into a definitive agreement to
acquire Oriental Wave Holdings Ltd. The proposed acquisition is subject to a
number of conditions including regulatory and shareholders' approval. If the
proposed acquisition is consummated, the combined company will have diverse and
proven product lines under 3 divisions: a Pharma division for prescription and
over-the-counter generic drugs, a Chemical division for bulk pharmaceutical
chemicals such as Clavulanic Acid, 7-ACA and sterilized bulk drug production,
and a Biotech division for EPO and in-licensed G-CSF. For details, please refer
to the press release on June 14, 2004 - "Dragon and Oriental Wave Announce the
Signing of Definitive Agreement to Create a Competitive and Growth Oriented
Pharmaceutical Company"
For further information, please contact Garry Wong (email: ir@dragonbiotech.com)
at (604) 669-8817 or North America toll free at 1-877-388-3784 or visit our web
site at www.dragonpharma.com or www.dragonbiotech.com.
Forward Looking Statement:
Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private
Securities Litigation Reform Act of 1995: All statements, other than historical
facts, included in this press release are forward-looking statements.
Forward-looking statements are not guarantees of future performance. They
involve risk, uncertainties and assumptions including risks discussed under
"Risks Associated With Dragon Pharmaceutical" in the Company's annual report on
Form 10-KSB, SEC File No.: 0- 27937 and other documents filed with the SEC. The
Company does not undertake the obligation to publicly revise these
forward-looking statements to reflect subsequent events or circumstances.
The foregoing may be deemed to be soliciting materials of Dragon in connection
with its definitive agreement to acquire Oriental Wave announced on June 14,
2004. This disclosure is being made in connection with Regulation of Takeovers
and Security Holder Communications (Release Nos. 33-7760 and 34-42055) adopted
by the Securities and Exchange Commission ("SEC") and Rule 14a-12 under the
Securities Exchange Act of 1934, as amended. Dragon shareholders and other
investors are urged to read the definitive proxy statement that Dragon will file
with the SEC and send to shareholders in connection with the proposed business
acquisition because it will contain important information about Dragon, Oriental
Wave and related matters. Dragon and its directors and executive officers may be
deemed to be participants in Dragon's solicitation of proxies from Dragon
shareholders in connection with the proposed acquisition. Information regarding
the participants and their security holdings can be found in Dragon's most
recent Form 10-KSB filed with the SEC, which is available from the SEC and
Dragon as described below, and the definitive proxy statement when it is filed
with the SEC. The definitive proxy statement will be available for free, both on
the SEC web site (http://www.sec.gov) and from Dragon as follows:
Garry Wong
Dragon Pharmaceutical, Inc
1900 - 1055 West Hastings Street, Vancouver, British Columbia, Canada V6E 2E9
Telephone: (604) 669-8817 or North America Toll Free: 1-877-388-3784
In addition to the preliminary proxy statement, Dragon files annual, quarterly
and special reports, proxy statements and other information with the SEC. You
may read and copy any reports, statements or other information filed by Dragon
at the SEC's public reference rooms at 450 Fifth Street, N.W., Washington, D.C.
20549 or at the SEC's other public reference rooms in New York and Chicago.
Please call the SEC at 1-800-SEC-0330 for further information on the public
reference rooms. Dragon filings with the SEC are also available to the public
from commercial document-retrieval services and on the SEC's web site at
http://www.sec.gov.